How spaceflight challenges human cardiovascular health.

Postflight orthostatic intolerance Spaceflight Associated Neuroocular syndrome cardiac atrophy cardiovascular remodelling commercial spaceflight countermeasure microgravity neck vein thrombosis

Journal

European journal of preventive cardiology
ISSN: 2047-4881
Titre abrégé: Eur J Prev Cardiol
Pays: England
ID NLM: 101564430

Informations de publication

Date de publication:
05 08 2022
Historique:
received: 12 10 2021
revised: 08 01 2022
accepted: 06 02 2022
pubmed: 12 2 2022
medline: 10 8 2022
entrez: 11 2 2022
Statut: ppublish

Résumé

The harsh environmental conditions in space, particularly weightlessness and radiation exposure, can negatively affect cardiovascular function and structure. In the future, preventive cardiology will be crucial in enabling safe space travel. Indeed, future space missions destined to the Moon and from there to Mars will create new challenges to cardiovascular health while limiting medical management. Moreover, commercial spaceflight evolves rapidly such that older persons with cardiovascular risk factors will be exposed to space conditions. This review provides an overview on studies conducted in space and terrestrial models, particularly head-down bedrest studies. These studies showed that weightlessness elicits a fluid shift towards the head, which likely predisposes to the spaceflight-associated neuro-ocular syndrome, neck vein thrombosis, and orthostatic intolerance after return to Earth. Moreover, cardiovascular unloading produces cardiopulmonary deconditioning, which may be associated with cardiac atrophy. In addition to limiting physical performance, the mechanism further worsens orthostatic tolerance after return to Earth. Finally, space conditions may directly affect vascular health; however, the clinical relevance of these findings in terms of morbidity and mortality is unknown. Targeted preventive measures, which are referred to as countermeasures in aerospace medicine, and technologies to identify vascular risks early on will be required to maintain cardiovascular performance and health during future space missions.

Identifiants

pubmed: 35148376
pii: 6527203
doi: 10.1093/eurjpc/zwac029
doi:

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1399-1411

Commentaires et corrections

Type : CommentIn

Informations de copyright

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2022. For permissions, please email: journals.permissions@oup.com.

Déclaration de conflit d'intérêts

Conflict of interest: J.J. has served as a consultant for Novartis, Boehringer-Ingelheim, and Novo-Nordisk and is cofounder of Eternygen GmbH. The other authors declare that they have no conflict of interest.

Auteurs

Peter Jirak (P)

University Clinic for Internal Medicine II, Department of Cardiology and Intensive Care Medicine, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria.

Moritz Mirna (M)

University Clinic for Internal Medicine II, Department of Cardiology and Intensive Care Medicine, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria.

Richard Rezar (R)

University Clinic for Internal Medicine II, Department of Cardiology and Intensive Care Medicine, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria.

Lukas J Motloch (LJ)

University Clinic for Internal Medicine II, Department of Cardiology and Intensive Care Medicine, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria.

Michael Lichtenauer (M)

University Clinic for Internal Medicine II, Department of Cardiology and Intensive Care Medicine, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria.

Jens Jordan (J)

Institute of Aerospace Medicine, German Aerospace Medicine (DLR), Cologne, Germany.
Chair of Aerospace Medicine, Medical Faculty, University of Cologne, Cologne, Germany.

Stephan Binneboessel (S)

Division of Cardiology, Pulmonology, and Vascular Medicine, Medical Faculty, University Duesseldorf, Duesseldorf, Germany.

Jens Tank (J)

Institute of Aerospace Medicine, German Aerospace Medicine (DLR), Cologne, Germany.

Ulrich Limper (U)

Institute of Aerospace Medicine, German Aerospace Medicine (DLR), Cologne, Germany.
Department of Anaesthesiology and Critical Care Medicine, Merheim Medical Center, Witten/Herdecke University, Cologne, Germany.

Christian Jung (C)

Division of Cardiology, Pulmonology, and Vascular Medicine, Medical Faculty, University Duesseldorf, Duesseldorf, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH